Celerion

Celerion (operating at celerion.com) is a specialized clinical research organization (CRO) focused on early-phase drug development and translational medicine. Founded in 2010 by Dr. Thornton, who serves as President and CEO, the company is headquartered in Lincoln, Nebraska. Celerion bridges the gap between laboratory research and clinical trials by delivering bioanalytical services and applied translational expertise, ensuring faster, more accurate drug candidate evaluation. Unlike traditional CROs that may lack deep early-phase specialization, Celerion streamlines the transition from preclinical testing to human trials, reducing development timelines and improving success rates. Its integrated approach—combining pharmacokinetics, pharmacodynamics, and safety assessments—empowers biopharmaceutical companies to make data-driven decisions early in the pipeline. With a global footprint spanning Lincoln (NE), Phoenix (AZ), and Belfast (UK), Celerion supports researchers and sponsors in accelerating breakthroughs for diseases ranging from rare disorders to infectious diseases.